Hypogonadism in a Man With Cystic Fibrosis and an Unusually Low Serum Testosterone: A Cautionary Tale
AACE Clinical Case Reports · 2025-01 · 11 (1) · 32-35
DOI: 10.1016/j.aace.2024.09.008 ↗Kurz gefasst
Fallbericht in der Zeitschrift AACE Clinical Case Reports, 2025-01. Verfasst von Khemaporn Lertdetkajorn und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Metabolism, and Lipids, Emory University School of Medicine, Atlanta, Georgia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background/Objective: Men with cystic fibrosis (CF) have a high prevalence of low testosterone levels. A recent retrospective study demonstrated a quarter of a cohort of men with CF had serum testosterone levels below 300 ng/dL. The evaluation of hypogonadism is of increasing clinical importance in order to prevent unfavorable outcomes. Herein we present a 31-year-old man with CF and a relatively low serum testosterone value who was found to have an additional unsuspected cause of male hypogonadism. Case Report: The patient was a 31-year-old man with history of CF who was referred to endocrinology clinic for the evaluation of hypogonadism. Serum testing revealed a total testosterone of 175 ng/mL (296-1377), luteinizing hormone 2.8 mIU/mL (1.2-8.6), and a prolactin of 341 ng/mL (3-13). A brain magnetic resonance imaging was obtained, which revealed a 1 cm hypoenhancing left sellar lesion. He was started on cabergoline. His testosterone increased to 707 ng/dL after a year on cabergoline treatment. His prolactin decreased to 12 ng/mL after a year of treatment. The pituitary adenoma decreased 50% in size 2 years after cabergoline was initiated.
Discussion
The most common etiologies of CF are recurrent infections, chronic inflammation, and glucocorticoid administration, which lead to both hypothalamic-pituitary dysregulation and primary hypogonadism. However, other less common causes of hypogonadism can also be found in CF.
Conclusion
We suggest that all men with cystic fibrosis found to have hypogonadism undergo additional evaluation for causes of hypogonadism prior to treatment with testosterone.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Metabolism, and Lipids, Emory University School of Medicine, Atlanta, Georgia.
- Division of Pulmonary, Allergy, Critical Care and Sleep, Emory University School of Medicine, Atlanta, Georgia.
Zitieren
APA
Lertdetkajorn, K., Cobb, C., Kapolka, R. J., Hunt, W. R., & Tangpricha, V. (2025). Hypogonadism in a Man With Cystic Fibrosis and an Unusually Low Serum Testosterone: A Cautionary Tale. AACE Clinical Case Reports, 11(1), 32-35. https://doi.org/10.1016/j.aace.2024.09.008
Vancouver
Lertdetkajorn K, Cobb C, Kapolka RJ, Hunt WR, Tangpricha V. Hypogonadism in a Man With Cystic Fibrosis and an Unusually Low Serum Testosterone: A Cautionary Tale. AACE Clinical Case Reports. 2025;11(1):32-35. doi:10.1016/j.aace.2024.09.008
BibTeX
@article{Lertdetkajorn2025,
author = {Lertdetkajorn, Khemaporn and Cobb, Crystal and Kapolka, Rebecca J and Hunt, William R and Tangpricha, Vin},
title = {Hypogonadism in a Man With Cystic Fibrosis and an Unusually Low Serum Testosterone: A Cautionary Tale},
journal = {AACE Clinical Case Reports},
year = {2025},
volume = {11},
number = {1},
pages = {32--35},
doi = {10.1016/j.aace.2024.09.008}
}
EUVIMED